These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34375617)

  • 21. Novel and emerging treatments for Aicardi-Goutières syndrome.
    Tonduti D; Fazzi E; Badolato R; Orcesi S
    Expert Rev Clin Immunol; 2020 Feb; 16(2):189-198. PubMed ID: 31855085
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic Approaches to Type I Interferonopathies.
    Bienias M; Brück N; Griep C; Wolf C; Kretschmer S; Kind B; Tüngler V; Berner R; Lee-Kirsch MA
    Curr Rheumatol Rep; 2018 Apr; 20(6):32. PubMed ID: 29679241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Update on Autoinflammatory Diseases: Interferonopathies.
    Davidson S; Steiner A; Harapas CR; Masters SL
    Curr Rheumatol Rep; 2018 May; 20(7):38. PubMed ID: 29846818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlling inflammation: contemporary treatments for autoinflammatory diseases and syndromes.
    Sterba G; Sterba Y
    Dermatol Clin; 2013 Jul; 31(3):507-11. PubMed ID: 23827252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype.
    Clarke SLN; Robertson L; Rice GI; Seabra L; Hilliard TN; Crow YJ; Ramanan AV
    Pediatr Rheumatol Online J; 2020 May; 18(1):37. PubMed ID: 32398023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.
    de Koning HD; Schalkwijk J; van der Meer JW; Simon A
    J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment.
    Havnaer A; Han G
    Am J Clin Dermatol; 2019 Aug; 20(4):539-564. PubMed ID: 30997665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors.
    Pin A; Tesser A; Pastore S; Moressa V; Valencic E; Arbo A; Maestro A; Tommasini A; Taddio A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
    Yamaoka K
    Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoinflammatory disorders, pain, and neural regulation of inflammation.
    Chen MC; Meckfessel MH
    Dermatol Clin; 2013 Jul; 31(3):461-70. PubMed ID: 23827248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of autoinflammatory syndromes.
    Hoffman HM
    J Allergy Clin Immunol; 2009 Dec; 124(6):1129-38; quiz 1139-40. PubMed ID: 20004774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK inhibitors in chronic plaque psoriasis: What is known so far.
    Plachouri KM; Georgiou S
    Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoinflammatory diseases in dermatology: CAPS, TRAPS, HIDS, FMF, Blau, CANDLE.
    Tripathi SV; Leslie KS
    Dermatol Clin; 2013 Jul; 31(3):387-404. PubMed ID: 23827243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulating against the dysregulation: new treatment options in autoinflammation.
    Kallinich T
    Semin Immunopathol; 2015 Jul; 37(4):429-37. PubMed ID: 26059720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoinflammatory syndromes.
    Cush JJ
    Dermatol Clin; 2013 Jul; 31(3):471-80. PubMed ID: 23827249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
    Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
    Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
    Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
    Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.